Janneke E. Jaspers

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

18h-index3.2kcitations81works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(39), DNA Repair Mechanisms(13), Lung Cancer Research Studies(12), Cancer therapeutics and mechanisms(11), Lung Cancer Treatments and Mutations(9)

Publications81 total

Supplementary Tables from <i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
2023Open Access
Supplementary Figure Legends 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Figures S1 - S5 from <i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
2023Open Access
Supplementary Figures 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Figure Legends 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Figures S1 - S5 from <i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
2023Open Access
Supplementary Figures 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Data from <i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
2023Open Access
Data from <i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
2023Open Access
Supplementary Tables from <i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer
2023Open Access
Data from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Data from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Materials and Methods, Supplementary Tables 1 through 3, and Supplementary Figure 1 from The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
2023Open Access
Data from The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
2023Open Access
Supplementary Materials and Methods, Supplementary Tables 1 through 3, and Supplementary Figure 1 from The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
2023Open Access
Data from The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
2023Open Access
Supplementary Methods from Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors
2023Open Access
Supplementary Figure 2 from 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Sven Rottenberg(42), Ariena Kersbergen(31), Jos Jonkers(28), Piet Borst(19), Wendy Sol(15), Serge A.L. Zander(13), Natalia Issaeva(13), Huw D. Thomas(13), Tatjana Djurenovic(13), Ivaylo Stoimenov(13), Suzanne Kyle(13), Nicholas Pedley(13), Ponnari Gottipati(13), Rafal Zur(13), Kate Sleeth(13), Vicky Chatzakos(13), Evan A. Mulligan(13), Cecilia Lundin(13), Evgenia Gubanova(13), Adrian L. Harris(13)